Leading allergy experts to convene in Istanbul to explore how science, prevention and policy can reduce the global impact of allergic diseases June 12, 2026 01:00 ET | Source: European Academy of Allergy and Clinical Immunology ZURICH, June 12, 2026 (GLOBE NEWSWIRE) — As allergic diseases continue to affect hundreds of millions of people worldwide and place […]
June 11, 2026 04:36 ET | Source: Global Liver Institute Washington, D.C., June 11, 2026 (GLOBE NEWSWIRE) — Global Fatty Liver Day 2026 comes at a pivotal moment for liver health worldwide. Following the adoption of the landmark World Health Organization (WHO) Resolution on Reducing the Burden of Noncommunicable Diseases, communities around the world are increasingly recognizing steatotic liver disease (SLD)
June 11, 2026 03:04 ET | Source: Curium BOSTON, June 11, 2026 (GLOBE NEWSWIRE) — Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan. 64Cu-PSMA-I&T is a PET radiopharmaceutical targeting PSMA. 64Cu-PSMA-I&T is being assessed as a PET agent labeled
June 10, 2026 12:03 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. “This acquisition reflects our Pivot to
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation June 10, 2026 08:00 ET | Source: Kyowa Kirin PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further
The partnership brings Nucleus’ advanced carrier and embryo screening to Hawaii’s largest IVF practice June 09, 2026 09:00 ET | Source: Nucleus Genomics Inc. NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics today announced an IVF+ partnership with the Fertility Institute of Hawaii, bringing its advanced carrier screening and embryo analysis to Hawaii’s largest IVF practice. Through the collaboration, patients
June 09, 2026 04:00 ET | Source: Royal Philips June 9, 2026 Amsterdam, the Netherlands – AI is already saving clinicians the equivalent of over 16 working days a year and helping them see more patients, but healthcare systems risk falling behind because of inadequate training and fragmented infrastructure. That’s according to findings from Philips’ Future Health Index
June 08, 2026 13:23 ET | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed
June 08, 2026 13:15 ET | Source: Vantive GLASGOW, Scotland, June 08, 2026 (GLOBE NEWSWIRE) — Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, reports two late-breaking clinical studies indicating HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer provides similar (statistically non-inferior) all-cause mortality and major cardiovascular outcomes* compared with online hemodiafiltration (OL-HDF).1,2 The randomized
June 08, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with AUSTEDO® and AUSTEDO XR®. The
June 07, 2026 14:30 ET | Source: Boehringer Ingelheim Limited Ingelheim, Germany – Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without
June 05, 2026 11:48 ET | Source: EnGeneIC SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) — EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill Neurosurgery Brain Tumor Center Gala event in New York City. The award was presented to Joint-CEO’s and
June 05, 2026 11:30 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life
June 05, 2026 04:30 ET | Source: Vantive New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis Findings highlight the importance of coordinated, patient-centric kidney care, including early referral,
June 04, 2026 08:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company’s growing biosimilars portfolio and expanding its presence in ophthalmology. The launch reflects Teva’s strategy to build a leading biosimilars business in
